spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Defibrotide 

 HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Feb 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Nov 2019
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Jun 2019
Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Nov 2018
Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Aug 2018
Vyxeos(R) Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Mar 2018
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2017
Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 May 2016
Jazz Pharmaceuticals And Celator Pharmaceuticals Announce Agreement For Jazz Pharmaceuticals To Acquire Celator For $30.25 Per Share
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 14 Nov 2013
Defibrotide Granted Orphan Drug Status in Australia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Oct 2013
Gentium Receives Marketing Authorization From the European Commission for Defitelio(R) (Defibrotide)
Biopharmaceuticals Regulatory Product Launch
 HSMN NewsFeed - 2 Oct 2013
Salvatore Calabrese Appointed to Chief Operating Officer at Gentium S.p.A.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2013
Gentium Receives Positive Opinion From EMA's CHMP for Defitelio
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Feb 2013
Gentium Provides Update on the Review of Defibrotide Marketing Authorization
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 May 2012
Gentium Appoints PharmaSwiss, S.A. as Exclusive Distributor of Defibrotide in Central and Eastern European Countries
Biopharmaceuticals Distribution
 HSMN NewsFeed - 27 Feb 2012
The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2012
Gentium Appoints Swedish Orphan Biovitrum AB as Exclusive Distributor of Defibrotide in Nordic and Baltic Territories
Biopharmaceuticals Distribution
 HSMN NewsFeed - 29 Dec 2011
Gentium Provides Update on MAA Process for Defibrotide in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Mar 2011
Gentium Appoints Adrian Haigh as Senior Vice President of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2010
Gentium Announces Management Changes and Corporate Restructuring
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Aug 2009
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Biopharmaceuticals
 HSMN NewsFeed - 3 Jan 2007
Gentium Acquires Italian Defibrotide Marketing Rights from Crinos
Biopharmaceuticals
 HSMN NewsFeed - 11 Jul 2006
Gentium Announces Publication of Two Independent Pediatric Studies of Defibrotide
Biopharmaceuticals
 HSMN NewsFeed - 25 May 2006
Gentium Strengthens U.S. Presence and Adds Personnel
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
Defibrotide
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.